Cis-diamminedichloroplatinum(II) augments expression of tumor-associated antigens on human gastric cancer cell line KATO-3 and increases susceptibility and binding of tumor cells to various cytotoxic effector cells

Journal of Surgical Oncology

Volumn 62, Issue 3, 1996, Pages 162-170

  Hayashi, Hitoshi ^a   Nio, Yoshinori ^b   Kawabata, Kazuya ^a   Araya, Shinichi ^a   Imamura, Masayuki ^a  

^a KYOTO UNIVERSITY   (Japan)

^b SHIMANE UNIVERSITY   (Japan)

Author keywords

antigen modulation; chemoimmuno modulation; cisplatin; cytotoxic T lymphocytes (CTL); human leukocyte antigen (HLA); lymphokine activated killer (LAK) cell

Indexed keywords

BETA 2 MICROGLOBULIN; CISPLATIN; HLA ANTIGEN CLASS 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1;

ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; CELL INTERACTION; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOSTIMULATION; PRIORITY JOURNAL; STOMACH CANCER; T LYMPHOCYTE ACTIVATION;

ADJUVANTS, IMMUNOLOGIC; ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; ANTINEOPLASTIC AGENTS; CARCINOMA; CISPLATIN; CYTOTOXICITY TESTS, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; HLA ANTIGENS; HUMANS; KILLER CELLS, LYMPHOKINE-ACTIVATED; LYMPHOCYTE CULTURE TEST, MIXED; STIMULATION, CHEMICAL; STOMACH NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0029946618     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9098(199607)62:3<162::AID-JSO4>3.0.CO;2-5     Document Type: Article

References (32)

1. Hersh EM: Immunosuppressive agents: "Antineoplastic and Immuno-suppressive Agents." New York: Springer-Verlag, 1974, p 577-617.
2. Ehrke MJ, Mihich E: Immunoregulaton by cancer chemo-therapeutic agents. In: "The Reticuloendothelial System: A Comprehensive Treatise." New York: Plenum Press, 1985, p 309-347.
3. Nio Y, Ohgaki K, Tobe T: Induction by cyclophosphamide administration of two distinct anti-tumor effector cells at tumor site and spleen of mice transplanted with MOPC-104E plasmacytoma. J Clin Lab Immunol 29:37-43, 1989.
4. Nio Y, Imai S, Shiraishi T, et al.: Lymphocytes anticancer chemosensitivity testing in vitro: An approach to predict immunosuppressive effect of anticancer agents. J Clin Lab Immunol, 29:141-145, 1989.
5. Goedegebuure PS, Braakman E, Segal DM, et al.: Lymphocyte leukocyte function-associated antigen 1 interacting with target cell intercellular adhesion molecule 1 co-activates cytolysis triggered via CD16 or the receptor involved in major histocompatibility antigen-unrestricted lysis. Int Immunol 2:1213-1220, 1990,
6. Pascoe JM, Roberts JJ: Interactions between mammalian cell DNA and inorganic platinum compounds. I. DNA interstrand crosslinking and cytotoxic properties of platinum (II) compounds. Biochem Pharmacol 23:1345-1357, 1974.
7. Rosenberg B: Enhanced antigenicity as a possible mode of action of platinum antitumor drugs: "Advances in Antimicrobial and Antineoplastic Chemotherapy," Vol II. Baltimore: University Park Press, 1980, p 101-107.
8. Kleinerman ES, Zwelling LA: Enhancement of naturally occurring human spontaneous monocyte-mediated cytotoxicity by cis-diamminedichloroplatinum (II). Cancer Res 40:3099-3102, 1980.
9. Lichtenstein AK, Pende D: Enhancement of natural killer cytotoxicity by cis-Diamminedichloroplatinum (II) in vivo and in vitro. Cancer Res, 46:639-644, 1986.
10. Sohdi A, Pai K, Singh RK, et al.: Activation of human NK cells and monocytes with cisplatin in vitro. Int J Immunopharmac 12:893-898, 1990.
11. Mizutani Y, Nio Y, Yoshida O: Modulation by cis-diammine-dichloroplatinum (II) of the susceptibilities of human T24 lined and freshly separated autologous urinary bladder transitional carcinoma cells to peripheral blood lymphocytes and lymphokine activated killer cells. J Urol 147:505-510, 1992.
12. Mizutani Y, Bonavida B, Nio Y, et al.: Enhanced susceptibility of cis-diamminedichloroplatinum-treated K562 cells to lysis by peripheral blood lymphocytes and lymphokine activated killer cells. Cancer 71:1313-1321, 1993.
13. Kumagai S, Ishida K, Imura H: Positive different mechanisms of B cell activation in systemic lupus erythematosis and rheumatoid arthritis: Opposite expression of low-affinity receptors for IgE (CD23) on their peripheral B cells. Clin Exp Immunol 78:348-353, 1989.
14. Nio Y, Imai S, Shiraishi T, et al.: Chemosensitivity correlation between the primary tumors and simultaneous metastatic lymph nodes of patients evaluated by DNA synthesis inhibition assay. Cancer 65:1273-1278, 1990.
15. Rosenberg B: Cisplatin: Its history and possible mechanism of action. In: "Current Status and New Developments." New York; Academic Press, 1980, p 9-20.
16. Kleinerman ES, Zwelling LA: Effects of cisplatin, bleomycin and DITC on immune function in vitro and in vivo. Clin Immunol Allergy 4:279-294, 1984.
17. Zinkernagel RM, Doherty PC: MHC restricted T cells. Studies on the biological role of polymorphic major transplantation antigens determining T cell restriction specificity function and responsiveness. Adv Immunol 27:51-177, 1979.
18. Ploegh HL, Orr HT, Strominge JL: Major histocompatibility antigens: The human (HLA-A, B, C) and murine (H-2K, H-2D) class I molecules. Cell 24:287-299, 1981.
19. Carreno BM, Winter CC, Taurog JD, et al.: Residues in pockets B and F of HLA-B27 are critical in the presentation of an influenza A virus nucleoprotein peptide and influence the stability of peptideMHC complexes. Int Immunol 5:353-360, 1993.
20. Eckels DD, Lake P, Lamb JR, et al.: SB-restricted presentation of influenza and herpes simplex virus antigen to human T lymphocyte clones. Nature (London) 301:716-718, 1983.
21. Gary JN, Elizabeth GN, Zhi-yong Y: Direct gene transfer with DNA-liposome complexes in melanoma: Expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci 90: 11307-11311, 1993.
22. Garrido A, Perez M, Delgado C, et al.: The influence of class I H-2 gene expression on local tumor growth. Description of a model obtained from clones derived from a solid BALB/C tumor. Exp Clin Immunogenetics 3:98-110, 1986.
23. Lotze MT, Grimm EA, Mazumder A, et al.: Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res 41:4420-4425, 1981.
24. Ljunggren HG, Karre K: In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today 11:237-244, 1990.
25. Bertschmann M, Kaesermann D, Keller R: MHC class-I antigen deficiency malignancy and susceptibility of P815 mastocytoma to NK and macrophage killing. Int J Cancer 46:739-744, 1990.
26. Ostrand-Rosenberg S, Cole GA, Nishimura MI, et al.: Transfection and expression of syngeneic H-2 genes does not reduce malignancy of H-2 negative teratocarcinoma cells in the autologous host. Cell Immunol 128:152-164, 1990.
27. Neefjes JJ, Ploegh HL: Allele and locus-specific differences in cell surface expression and the association of HLA class I heavy chain and β2-microglobulin: differential effects of inhibition of glycosylation on class I subunit association. Eur J Immunol 18:801-810, 1988.
28. Momburg F, Koch JS: Selective loss of β2-microglobulin mRNA in human colon carcinoma. J Exp Med 169:309-314, 1989.
29. Larson RS, Springer TA: Structure and function of the leukocyte integrins. Immunol Rev 114:181-217, 1990.
30. Kraus E, Schneider-Schaulies S, Miyasaka M, et al.: Augmentation of major histocompatibility complex class I and ICAM-I expression on glial cells following measles virus infection: evidence for the role of type-1 interferon. Eur J Immunol 22:175-182, 1992.
31. Basu S, Sohdi A: Increased release of interleukin-1 and tumor necrosis factor by interleukin-2-induced lymphokine-activated killer cells in the presence of cisplatin and FK-565. Immunol Cell Biol 70:15-24, 1992.
32. Sohdi A, Pai K: Studies on the release of interleukin-1 (IL-1), tumor necrosis factor (TNF) and lysozyme from human non-adherent mononuclear cells (nMNC) in vitro after treatment with cisplatin and other biological modifiers. Neoplasma 39:4-10, 1992.